JP Morgan Maintains Overweight on Ascentage Pharma Group, Lowers Price Target to $33

Benzinga · 1d ago
JP Morgan analyst Brian Cheng maintains Ascentage Pharma Group (NASDAQ:AAPG) with a Overweight and lowers the price target from $46 to $33.